Even if the US exempts generic drugmakers from this rule, the danger lies in future creep, as it could later be applied to complex generics and biologics

xUnited States President Donald Trump’s announcement to levy a 100 per cent tariff on branded or patented pharmaceutical imports — unless the maker is actively building a facility in the United States — shows his mercantile thought process and marks yet another turn in global trade tensions.

While the restrictions were presented as an attempt to achieve self-reliance in US pharmaceutical manufacturing, this move threatens to upend the global drug industry, which relies heavily on Indian pharmaceutical companies for unbranded generics. Though the US President did not specifically mention generic drugs in his announcement, the White House

See Full Page